Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, 2026, the Compensation Committee of Recursion's Board of ...

Precedence Research, a leading strategic research firm, presents a comprehensive analysis of the AI-driven bioengineering ...

Is On Investors’ Radar Today Recursion Pharmaceuticals (RXRX) shares recently closed at US$3.98, with the stock showing a negative return over the past month and past 3 months, which may prompt ...

It's a potential game-changing technology. The company just needs to prove to the world that it works well enough.

Last year's weakness is ultimately an improved entry opportunity for long-term-minded investors.

Issued on behalf of VentriPoint Diagnostics Ltd. VANCOUVER, BC, Jan. 29, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary – The global AI medical imaging market exploded to a staggering $2.57 ...

Multi-OS devices are finally becoming viable as Google, Microsoft, and Lenovo rethink how operating systems coexist across modern hardware. image: envato/melis82 The tech world has seen its share of ...

Earlier in January, Recursion Pharmaceuticals updated investors at the JP Morgan Healthcare Conference on its AI-powered drug discovery platform, clinical programs, and collaborations with partners ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...

Salt Lake City, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, ...

Choosing between iOS 26 on the iPhone 17 Pro Max and Oxygen OS 16 on the OnePlus 15 presents a challenge for users seeking the best operating system for their needs. Both platforms bring unique ...